Wave Life Sciences to Receive $12M Milestone Payment from GSK
Wave Life Sciences announced it is set to receive a $12 million milestone payment from GlaxoSmithKline (GSK) following the selection of a liver-targeted candidate for further research under their ongoing collaboration. The RNA medicines in development utilize Wave’s SpiNA design technology and GalNAc-siRNA platform, which are designed to enhance drug delivery efficiency. The news led to an increase in premarket trading activity for Wave Life Sciences (WVE), reflecting investor optimism about the progress of its research partnership with GSK. This milestone underscores continued interest from a major pharmaceutical player in advancing RNA-based therapies using Wave’s proprietary technology, potentially boosting long-term value and visibility for the company. The collaboration highlights growing momentum around next-generation RNA therapeutics, particularly those targeting liver diseases.
